Evidence map›Paper›PMID 42168578›Full record

Articlenpj antimicrobials and resistance2026

Impact of co-amoxiclav versus amoxicillin on the gastrointestinal microbiota in sub-Saharan children hospitalized with pneumonia.

Juan Pablo Rodriguez-Ruiz, Servaas Hiel, Victor Musiime, Veronica Mulenga, Hilda A Mujuru, Shabir A Madhi, David P Moore, Moherndran Archary, Michelle Clements, A Sarah Walker and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in npj antimicrobials and resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juan Pablo Rodriguez-RuizLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Servaas HielLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Victor MusiimeDepartment of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Veronica MulengaUniversity Teaching Hospital, Lusaka, Zambia.
Hilda A MujuruDepartment of Paediatrics and Child Health, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Shabir A MadhiSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
David P MooreSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Moherndran ArcharyAfrica Health Research Institute, Durban, South Africa.
Michelle ClementsMRC Clinical Trials Unit at University College London, University College London, London, UK.
A Sarah WalkerMRC Clinical Trials Unit at University College London, University College London, London, UK.
Julia A BielickiDepartment of Paediatric Infectious Diseases, University of Basel, Basel, Switzerland.
Michael SharlandCentre for Neonatal and Paediatric Infection, City St George's University of London, London, UK.
Surbhi Malhotra-KumarLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium. surbhi.malhotra@uantwerpen.be.

Funding

EDCTP2 RIA2017MC
6 · The paper itself

Abstract

Community-acquired pneumonia (CAP) causes high pediatric mortality especially in sub-Saharan Africa. In a secondary analysis of samples from the PediCAP trial (ISRCTN63115131), we tracked gastrointestinal resistome and microbiota dynamics of 149 children (<6 years) from South Africa, Zambia, Zimbabwe and Uganda presenting with severe CAP. Patients received initial WHO-standard IV therapy before being randomized to continue IV therapy or step-down to oral amoxicillin or co-amoxiclav for different total treatment durations. Samples were obtained after starting IV antibiotics, at discharge, and at four weeks follow-up. Microbiota dynamics were strongly associated with age and country of origin with specific bacterial genera unique to each country. Oral step-down to either antibiotic regimen or duration did not show any differential effects on the gastrointestinal microbiota and resistome dynamics compared to continuous IV therapy. The data of this secondary analysis complement the primary PediCAP trial analysis, supporting earlier hospital discharge for paediatric CAP patients.

Identifiers

PMID42168578
PMCPMC13530132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.